Gujarat Themis Biosyn Limited Share Price

Equities

GUJTHEM6

INE942C01045

Pharmaceuticals

Market Closed - Bombay S.E. 11:23:38 26/04/2024 BST 5-day change 1st Jan Change
408.7 INR +0.99% Intraday chart for Gujarat Themis Biosyn Limited +5.94% +59.31%

Financials

Sales 2022 1.15B 13.78M 1.1B Sales 2023 1.49B 17.87M 1.43B Capitalization 9.97B 120M 9.57B
Net income 2022 436M 5.23M 419M Net income 2023 580M 6.96M 557M EV / Sales 2022 4.97 x
Net cash position 2022 209M 2.5M 200M Net cash position 2023 84.84M 1.02M 81.46M EV / Sales 2023 6.64 x
P/E ratio 2022
13.6 x
P/E ratio 2023
17.2 x
Employees 109
Yield 2022
1.47%
Yield 2023
0.79%
Free-Float 27.98%
More Fundamentals * Assessed data
Dynamic Chart
Gujarat Themis Biosyn Limited Approves an Interim Dividend for the Year 2023-24 CI
Gujarat Themis Biosyn Limited Approves Interim Dividend for the Financial Year 2023-24 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Gujarat Themis Biosyn Names New CEO MT
Gujarat Themis Biosyn Limited Appoints Tapas Guha Thakurata as Chief Executive Officer CI
Gujarat Themis Biosyn Board Declares Interim Dividend for Fiscal 2023 MT
Gujarat Themis Biosyn Limited Approves Declaration of an Interim Dividend for the Financial Year 2022-23 CI
Gulf Oil Lubricants' Net Profit Slides in Fiscal Q2 MT
Gujarat Themis Biosyn's Net Profit Climbs in Fiscal Q2 MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million. CI
More news
1 day+0.99%
1 week+5.94%
Current month+3.18%
1 month+10.62%
3 months+33.63%
6 months+95.74%
Current year+59.31%
More quotes
1 week
385.00
Extreme 385
423.00
1 month
361.50
Extreme 361.5
423.00
Current year
267.00
Extreme 267
423.00
1 year
145.41
Extreme 145.41
423.00
3 years
47.00
Extreme 47
423.00
5 years
6.28
Extreme 6.28
423.00
10 years
1.80
Extreme 1.8
423.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 06/08/14
Director of Finance/CFO - -
Compliance Officer - 11/05/21
Members of the board TitleAgeSince
Director/Board Member 66 30/03/06
Director/Board Member 49 24/10/08
Chairman 75 24/05/92
More insiders
Date Price Change Volume
26/04/24 408.7 +0.99% 41,547
25/04/24 404.7 -1.05% 113,875
24/04/24 409 +2.30% 287,262
23/04/24 399.8 -0.67% 69,054
22/04/24 402.5 +4.33% 140,869

Delayed Quote Bombay S.E., April 26, 2024 at 11:23 am

More quotes
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
More about the company
  1. Stock Market
  2. Equities
  3. GUJTHEM6 Stock